A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Background: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast.

Methods: We included participants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter and who met no criteria for starting ART according to World Health Organization (WHO) guidelines.

[Morbidity and mortality from infectious diseases at the Military Hospital of Abidjan, Côte d'Ivoire].

Objectives: To determine the proportion of infectious diseases and their lethality at the Abidjan Military Hospital.

Patients And Methods: This cross-sectional study examined the medical files of patients hospitalized in the internal medicine unit of the hospital during 2004.

Results: The study included 668 patients with 855 diseases, 579 of them infectious (67.

[Clinical and developmental aspects of care-related tetanus in the reference service of the teaching hospital of Abidjan].

A cross-sectional descriptive study was conducted from medical data of inpatients with tetanus in the Department of Infectious and Tropical Diseases of the University Hospital of Treichville in Abidjan from January 2003 to December 2007. In five years, 221 cases of tetanus have been hospitalized. The tetanus gateway was found in 188 patients (85%).

HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.

As antiretroviral therapy continues to scale-up in developing countries, there is concern that high levels of HIV drug resistance to antiretroviral drugs will occur. Here we describe rates of emergence of HIV-1 drug resistance and factors associated with their occurrence among adults who received antiretroviral therapy (ART) for >1 year through the Côte d'Ivoire national drug access program from 1998 to 2003. To detect genotypic drug resistance, we sequenced all 1- and 2-year specimens with detectable HIV RNA viral load.